| Name | ONC212 |
| Description | ONC212 [a fluorinated-ONC201 analogue] is a selective GPR132 agonist. |
| In vitro | In vitro studies using human acute myeloid leukemia (AML) cell lines, primary AML, and normal bone marrow (BM) samples demonstrate that ONC212 exerts prominent apoptogenic effects in AML, but not in normal BM cells, suggesting potential clinical utility[1]. |
| In vivo | ONC212 is active in pancreatic cancer as single agent or in combination with 5-fluorouracil, irinotecan, oxaliplatin or RTK inhibitor crizotinib. Based on upregulation of pro-survival IGF1-R in some tumors, Founded an active combination of ONC212 with inhibitor AG1024, including in vivo[2]. |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.54 mM), Sonication is recommended. DMSO : 50 mg/mL (113.52 mM), Sonication is recommended.
|
| Keywords | ONC-212 | ONC212 | ONC 212 | Inhibitor | inhibit | GPR132 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Hematonosis Compound Library | NO PAINS Compound Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |